On June 24, 2024, REGENXBIO Inc. announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
To read REGENXBIO’s full press release, please click here.
